Annual report
9265.TEDINET S100WKIB
Period2024-06-01 → 2025-05-31
Filed2025-08-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥64.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales |
| Revenue | ¥61.6bn | 2023-06-01 → 2024-05-31 | Cons. | Net sales |
| Revenue | ¥58.2bn | 2022-06-01 → 2023-05-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥55.1bn | 2021-06-01 → 2022-05-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥70.1bn | 2020-06-01 → 2021-05-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥838m | 2024-06-01 → 2025-05-31 | Cons. | Operating income |
| Operating income | ¥967m | 2023-06-01 → 2024-05-31 | Cons. | Operating income |
| Ordinary income | ¥909m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.0bn | 2023-06-01 → 2024-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-06-01 → 2023-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2021-06-01 → 2022-05-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2020-06-01 → 2021-05-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥943m | 2024-06-01 → 2025-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥871m | 2023-06-01 → 2024-05-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥616m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥580m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥219m | 2022-06-01 → 2023-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥696m | 2021-06-01 → 2022-05-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥678m | 2020-06-01 → 2021-05-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥614m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss |
| Net income | ¥577m | 2023-06-01 → 2024-05-31 | Cons. | Profit loss |
| Total assets | ¥27.5bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥26.6bn | at 2024-05-31 | Cons. | Assets |
| Total assets | ¥24.6bn | at 2023-05-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.1bn | at 2022-05-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥24.3bn | at 2021-05-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥18.6bn | at 2025-05-31 | Cons. | Liabilities |
| Total liabilities | ¥18.0bn | at 2024-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥9.0bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥8.6bn | at 2024-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.9bn | at 2023-05-31v | Cons. | Net assets |
| Net assets / equity | ¥8.0bn | at 2022-05-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥7.6bn | at 2021-05-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.7bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥5.3bn | at 2024-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.7bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.3bn | at 2024-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2023-05-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2022-05-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.7bn | at 2021-05-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥617m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥878m | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.2bn | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥581m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥911m | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥19m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.1bn | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥107m | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥27m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥134m | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥240m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥335m | 2023-06-01 → 2024-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥209m | 2022-06-01 → 2023-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥229m | 2021-06-01 → 2022-05-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥137m | 2020-06-01 → 2021-05-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥249.79 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥227.96 | 2023-06-01 → 2024-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.83 | 2022-06-01 → 2023-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥272.67 | 2021-06-01 → 2022-05-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥265.77 | 2020-06-01 → 2021-05-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,640.22 | at 2025-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,429.08 | at 2024-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,097.34 | at 2023-05-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,126.18 | at 2022-05-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,969.03 | at 2021-05-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 32.6% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2023-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2022-05-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.2% | at 2021-05-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.0% | 2024-06-01 → 2025-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2023-06-01 → 2024-05-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2022-06-01 → 2023-05-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2021-06-01 → 2022-05-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.3% | 2020-06-01 → 2021-05-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 613 | at 2025-05-31 | Cons. | Number of employees |
| Employees | 606 | at 2024-05-31 | Cons. | Number of employees |
| Employees | 570 | at 2023-05-31v | Cons. | Number of employees |
| Employees | 574 | at 2022-05-31v | Cons. | Number of employees |
| Employees | 553 | at 2021-05-31d | Cons. | Number of employees |
| Revenue | ¥1.4bn | 2024-06-01 → 2025-05-31 | Standalone | Operating revenue1 |
| Revenue | ¥1.4bn | 2023-06-01 → 2024-05-31 | Standalone | Operating revenue1 |
| Revenue | ¥498m | 2022-06-01 → 2023-05-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥792m | 2021-06-01 → 2022-05-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥854m | 2020-06-01 → 2021-05-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥729m | 2024-06-01 → 2025-05-31 | Standalone | Operating income |
| Operating income | ¥763m | 2023-06-01 → 2024-05-31 | Standalone | Operating income |
| Ordinary income | ¥728m | 2024-06-01 → 2025-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥764m | 2023-06-01 → 2024-05-31 | Standalone | Ordinary income |
| Ordinary income | −¥16m | 2022-06-01 → 2023-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥227m | 2021-06-01 → 2022-05-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥347m | 2020-06-01 → 2021-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥728m | 2024-06-01 → 2025-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥764m | 2023-06-01 → 2024-05-31 | Standalone | Income before income taxes |
| Net income | ¥718m | 2024-06-01 → 2025-05-31 | Standalone | Profit loss |
| Net income | ¥767m | 2023-06-01 → 2024-05-31 | Standalone | Profit loss |
| Net income | −¥13m | 2022-06-01 → 2023-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥228m | 2021-06-01 → 2022-05-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥348m | 2020-06-01 → 2021-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.5bn | at 2025-05-31 | Standalone | Assets |
| Total assets | ¥8.0bn | at 2024-05-31 | Standalone | Assets |
| Total assets | ¥6.3bn | at 2023-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.5bn | at 2022-05-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥6.4bn | at 2021-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.8bn | at 2025-05-31 | Standalone | Liabilities |
| Total liabilities | ¥1.8bn | at 2024-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥6.8bn | at 2025-05-31 | Standalone | Net assets |
| Net assets / equity | ¥6.3bn | at 2024-05-31 | Standalone | Net assets |
| Net assets / equity | ¥5.8bn | at 2023-05-31v | Standalone | Net assets |
| Net assets / equity | ¥6.0bn | at 2022-05-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥6.0bn | at 2021-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥732m | at 2025-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥312m | at 2024-05-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥291.15 | 2024-06-01 → 2025-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥301.31 | 2023-06-01 → 2024-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.29 | 2022-06-01 → 2023-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.32 | 2021-06-01 → 2022-05-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥136.46 | 2020-06-01 → 2021-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥75 | 2024-06-01 → 2025-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2023-06-01 → 2024-05-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥48 | 2022-06-01 → 2023-05-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥82 | 2021-06-01 → 2022-05-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥90 | 2020-06-01 → 2021-05-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,741.18 | at 2025-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,521.27 | at 2024-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,272.88 | at 2023-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,360.07 | at 2022-05-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,360.75 | at 2021-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 79.2% | at 2025-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.2% | at 2024-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.2% | at 2023-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.4% | at 2022-05-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.8% | at 2021-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 11.0% | 2024-06-01 → 2025-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.7% | 2023-06-01 → 2024-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -0.2% | 2022-06-01 → 2023-05-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2021-06-01 → 2022-05-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2020-06-01 → 2021-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,553,000 | at 2025-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2024-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2023-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2022-05-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,553,000 | at 2021-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 30 | at 2025-05-31 | Standalone | Number of employees |
| Employees | 29 | at 2024-05-31 | Standalone | Number of employees |
| Employees | 30 | at 2023-05-31v | Standalone | Number of employees |
| Employees | 27 | at 2022-05-31v | Standalone | Number of employees |
| Employees | 24 | at 2021-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2024-06-01 → 2025-05-31 | ¥37m |
| Reconciling Itemsreconciling | revenue | 2024-06-01 → 2025-05-31 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2025-05-31 | −¥1.1bn |
| Medical Equipment Manufacturing And Salesreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥6m |
| Medical Equipment Manufacturing And Salesreportable segment | employees | at 2025-05-31 | 7 pure |
| Medical Equipment Manufacturing And Salesreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥219m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥219m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2024-06-01 → 2025-05-31 | −¥220m |
| Medical Equipment Salesreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥122m |
| Medical Equipment Salesreportable segment | employees | at 2025-05-31 | 561 pure |
| Medical Equipment Salesreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥64.2bn |
| Medical Equipment Salesreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥64.2bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| Medical Equipment Salesreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥2.2bn |
| Medical Mallreportable segment | depreciation | 2024-06-01 → 2025-05-31 | ¥14m |
| Medical Mallreportable segment | revenue | 2024-06-01 → 2025-05-31 | ¥72m |
| Medical Mallreportable segment | revenue external | 2024-06-01 → 2025-05-31 | ¥72m |
| Medical Mallreportable segment | segment profit | 2024-06-01 → 2025-05-31 | ¥5m |
| —segment total | depreciation | 2024-06-01 → 2025-05-31 | ¥143m |
| —segment total | revenue | 2024-06-01 → 2025-05-31 | ¥64.5bn |
| —segment total | revenue external | 2024-06-01 → 2025-05-31 | ¥64.5bn |
| —segment total | revenue intersegment | 2024-06-01 → 2025-05-31 | ¥0 |
| —segment total | segment profit | 2024-06-01 → 2025-05-31 | ¥2.0bn |
| Reconciling Itemsreconciling | depreciation | 2023-06-01 → 2024-05-31 | ¥27m |
| Reconciling Itemsreconciling | revenue | 2023-06-01 → 2024-05-31 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-06-01 → 2024-05-31 | −¥1m |
| Reconciling Itemsreconciling | segment profit | 2023-06-01 → 2024-05-31 | −¥1.2bn |
| Medical Equipment Manufacturing And Salesreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥2m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥267m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥267m |
| Medical Equipment Manufacturing And Salesreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥0 |
| Medical Equipment Manufacturing And Salesreportable segment | segment profit | 2023-06-01 → 2024-05-31 | −¥1m |
| Medical Equipment Salesreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥138m |
| Medical Equipment Salesreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥61.2bn |
| Medical Equipment Salesreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥61.2bn |
| Medical Equipment Salesreportable segment | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥0 |
| Medical Equipment Salesreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥2.2bn |
| Medical Mallreportable segment | depreciation | 2023-06-01 → 2024-05-31 | ¥16m |
| Medical Mallreportable segment | revenue | 2023-06-01 → 2024-05-31 | ¥68m |
| Medical Mallreportable segment | revenue external | 2023-06-01 → 2024-05-31 | ¥68m |
| Medical Mallreportable segment | segment profit | 2023-06-01 → 2024-05-31 | ¥0 |
| —segment total | depreciation | 2023-06-01 → 2024-05-31 | ¥157m |
| —segment total | revenue | 2023-06-01 → 2024-05-31 | ¥61.6bn |
| —segment total | revenue external | 2023-06-01 → 2024-05-31 | ¥61.6bn |
| —segment total | revenue intersegment | 2023-06-01 → 2024-05-31 | ¥1m |
| —segment total | segment profit | 2023-06-01 → 2024-05-31 | ¥2.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,479
| Item | Context | Value | Unit |
|---|---|---|---|
| Official title or position information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000OdaTakahiroMember | Original text (Japanese)取締役執行役員 | |
| Name information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000OdaTakahiroMember | Original text (Japanese)尾田 誠博 | |
| Date of birth information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000OdaTakahiroMember | 1975-01-27 | |
| Career summary information about directors and corporate auditors proposal (text) | FilingDateInstant_jpcrp030000-asr_E33393-000OdaTakahiroMember | Text · Plus | |
| Term of office information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000OdaTakahiroMember | Original text (Japanese)(注)2 | |
| Official title or position information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000TamenagaKazuhiroMember | Original text (Japanese)取締役(常勤監査等委員) | |
| Name information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000TamenagaKazuhiroMember | Original text (Japanese)為永 和博 | |
| Date of birth information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000TamenagaKazuhiroMember | 1961-04-01 | |
| Career summary information about directors and corporate auditors proposal (text) | FilingDateInstant_jpcrp030000-asr_E33393-000TamenagaKazuhiroMember | Text · Plus | |
| Term of office information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000TamenagaKazuhiroMember | Original text (Japanese)(注)3 | |
| Official title or position information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000KogaShinichiroMember | Original text (Japanese)取締役(監査等委員) | |
| Name information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000KogaShinichiroMember | Original text (Japanese)古閑 慎一郎 | |
| Date of birth information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000KogaShinichiroMember | 1955-11-11 | |
| Career summary information about directors and corporate auditors proposal (text) | FilingDateInstant_jpcrp030000-asr_E33393-000KogaShinichiroMember | Text · Plus | |
| Term of office information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000KogaShinichiroMember | Original text (Japanese)(注)3 | |
| Official title or position information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000YamashitaToshioMember | Original text (Japanese)取締役(監査等委員) | |
| Name information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000YamashitaToshioMember | Original text (Japanese)山下 俊夫 | |
| Date of birth information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000YamashitaToshioMember | 1957-01-31 | |
| Career summary information about directors and corporate auditors proposal (text) | FilingDateInstant_jpcrp030000-asr_E33393-000YamashitaToshioMember | Text · Plus | |
| Term of office information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000YamashitaToshioMember | Original text (Japanese)(注)3 | |
| Official title or position information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000OnodaMidoriMember | Original text (Japanese)取締役(監査等委員) | |
| Name information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000OnodaMidoriMember | Original text (Japanese)斧田 みどり | |
| Date of birth information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000OnodaMidoriMember | 1961-11-10 | |
| Career summary information about directors and corporate auditors proposal (text) | FilingDateInstant_jpcrp030000-asr_E33393-000OnodaMidoriMember | Text · Plus | |
| Term of office information about directors and corporate auditors proposal | FilingDateInstant_jpcrp030000-asr_E33393-000OnodaMidoriMember | Original text (Japanese)(注)3 | |
| Footnotes directors and corporate auditors proposal (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors proposal (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors proposal (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Name of group company holding largest amount of investment shares in group | CurrentYearInstant | Original text (Japanese)山下医科器械株式会社 | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | Original text (Japanese)事業関係の一層の強化 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)テルモ株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)（保有目的及び株式数が増加した理由）取引関係維持・強化を目的として保有しています。（定量的な保有効果）注１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)オリンパス株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)無 | |
| Footnotes specified investment shares held for purposes other than pure investment largest holding company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Name of securities investment equity securities reclassified from held for purposes other than pure investment to held for pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)株式会社メディカルサテライト | |
| Fiscal year of change in purpose of shareholding investment shares reclassified from held for purposes other than pure investment to held for pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)2021年５月期 | |
| Reason for change in purpose of shareholding and policy on holding or sale of shares after change investment shares reclassified from held for purposes other than pure investment to held for pure investment largest holding company | CurrentYearInstant_Row1Member | Text · Plus | |
| Name of securities investment equity securities reclassified from held for purposes other than pure investment to held for pure investment largest holding company | CurrentYearInstant_Row2Member | Acutus Medical,Inc | |
| Fiscal year of change in purpose of shareholding investment shares reclassified from held for purposes other than pure investment to held for pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)2021年５月期 | |
| Reason for change in purpose of shareholding and policy on holding or sale of shares after change investment shares reclassified from held for purposes other than pure investment to held for pure investment largest holding company | CurrentYearInstant_Row2Member | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |